6 recruiting. 6 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Recruiting 6 |
| Phase 2 | 2 | Recruiting 2 |
Follow Gallbladder Neoplasms: new trials by email Literature Review of Gallbladder Neoplasms trials Research Report on Gallbladder Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer Nanvuranlat, Physician's Best Choice - Advanced Biliary Tract Cancer, Biliary Tract Cancer (BTC) | Phase 3 | Recruiting | J-Pharma Co., Ltd. | 480 | 2026-05-11 | 2026-09-29 |
| A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) Rilvegostomig, Durvalumab, Gemcitabine/Cisplatin - Biliary Tract Cancer | Phase 3 | Recruiting | AstraZeneca | 1100 | 2025-12-04 | 2026-09-28 |
| Neoadjuvant Chemotherapy for Locally Advanced Gall Bladder Cancer : a Randomized Control Trial (NEOGB) neoadjuvant chemotherapy, curative surgery - Gall Bladder Carcinoma | Phase 3 | Recruiting | Rajiv Gandhi Cancer Institute & Research Center, India | 114 | 2025-01-01 | 2025-04-16 |
| Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer Zanidatamab, Cisplatin, Gemcitabine - Biliary Tract Cancer | Phase 3 | Recruiting | Jazz Pharmaceuticals | 286 | 2024-07-19 | 2026-10-28 |
| Radiation Therapy in Unresectable Gall Bladder Cancer Systemic therapy (Gemcitabine plus Cisplatin), RT, Systemic therapy (Gemcitabine plus oxaliplatin) - Gall Bladder Cancer | Phase 2 / Phase 3 | Recruiting | Tata Memorial Centre | 249 | 2024-03-07 | 2025-04-11 |
| DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations Trastuzumab, Pertuzumab - Haematological Malignancy, Colorectal Neoplasms | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2023-03-07 | 2025-12-02 |
Biliary Tract Neoplasms (4) · Cholangiocarcinoma (2) · Colorectal Neoplasms (1) · Hematologic Neoplasms (1) · Lung Neoplasms (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1) · Recurrence (1) · Salivary Gland Neoplasms (1) · Skin Neoplasms (1) · Urinary Bladder Neoplasms (1)
Biliary Tract Diseases (6) · Digestive System Diseases (6) · Digestive System Neoplasms (6) · Gallbladder Diseases (6) · Neoplasms by Site (6) · Neoplasms (5) · Adenocarcinoma (2) · Biliary Tract Neoplasms (2) · Carcinoma (2) · Neoplasms by Histologic Type (2) · Neoplasms, Glandular and Epithelial (2) · Adnexal Diseases (1) · Colonic Diseases (1) · Disease Attributes (1) · Endocrine Gland Neoplasms (1)
Cisplatin (3) · Gemcitabine (3) · durvalumab (3) · Oxaliplatin (2) · 130-nm albumin-bound paclitaxel (1) · Folfox protocol (1) · Irinotecan (1) · Leucovorin (1) · Neoadjuvant Therapy (1) · Trastuzumab (1) · pembrolizumab (1) · pertuzumab (1) · zanidatamab (1)
AstraZeneca (1) · Cancer Research UK (1) · J-Pharma Co., Ltd. (1) · Jazz Pharmaceuticals (1) · Rajiv Gandhi Cancer Institute & Research Center, India (1) · Tata Memorial Centre (1)
India (4) · United Kingdom (3) · United States (3) · Belgium (2) · Brazil (2) · Canada (2) · China (2) · France (2) · Germany (2) · Italy (2) · Japan (2) · South Korea (2) · Spain (2) · Taiwan (2) · Turkey (Türkiye) (2)
Eric K Rowinsky, MD (1) · Ghassan Abou-Alfa, MD (1) · Matthew Krebs, Dr (1) · Shivakumar Gudi, MD (1) · Shivendra Singh, Mch Surgical gastroenterology (1)
2023 (1)